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Summary.-The growth and metastatic spread of human tumours in immuno-
suppressed hamsters is described. A variety of human tumours were transplanted
to the flank or the cheek pouch of the hamsters. Immunosuppression was obtained
by combined thymectomy and ATS treatment. In the period up to 4 months after
implantation, metastases to the lungs were observed with carcinomata of breast,
colon, larynx and kidney; also melanoma, rhabdomyosarcoma, fibrosarcoma and
teratoma of testis. Fourteen of 20 different tumours implanted metastasized to the
lungs. Only 2 tumours, a hypernephroma and a melanoma, became established
at the site of implantation; the remainder regressed even though the tumour was
proliferating in the lungs.
ANTITHYMOCYTE serum (ATS) has
been shown to be one ofthe most effective
immunosuppressive agents (Woodruff and
Anderson, 1963; James, 1967). It can be
sufficiently effective to allow skin xeno-
grafts to survive during the period ofATS
treatment (Shaffer et al., 1971). Thymec-
tomy is said to enhance the immuno-
suppressive effect of antilymphocyte
serum (ALS) in both skin and tumour
xenografts (Davis and Lewis, 1967;
Jeejeebhoy, 1970; Phillips and Gazet,
1970). Even when thymectomy and ATS
are combined, the survival of human
tumours transplanted subcutaneously in
rodents has been poor. It has always
been appreciated that factors other than
cell-mediated immunity could be respon-
sible for the failure of human tumour
specimens to survive. Thepresentexperi-
ments form a part of a study of the
growth and dispersion of human tumour
cells in immunosuppressed animals.
In the present experiments, tumours
from patients were implanted subcu-
taneously or into the cheek pouch. The
cheek pouch was chosen because it has
been shown to offer a degree ofprotection
against graft rejection (Toolan, 1955).
The animals were allowed to survive
irrespective of the apparent failure of the
graft to thrive. They were eventually
killed 120 days after implantation unless
they had already died as a result of
metastatic spread.
Macroscopical and microscopical
evidence of tumour was recorded both for
the site of implantation and for distant
sites, particularly the lungs.
Two control groups were included to
test the immunosuppressive effect of
combined thymectomy and ATS. In the
first group either hypernephroma or
carcinoma of the breast was implanted
into animals treated with thymectomy
together with ATS. In the second group
pieces from the same tumours were
implanted into animals treated with sham
thymectomy and normal rabbit serum
(NRS). The results are given in Table II.
MATERIALS AND METHODS
Experimental animals
Male and female Chester Beatty cream
hamsters were used. The hamsters haveL. M. COBB
been kept as a closed colony for more than 10
years and random bred.
Male New Zealand white rabbits weighing
between 3 and 4 kg were used for antiserum
production.
Thymectomy
The hamster litters were removed from
the dam for thymectomy at 13 or 14 days old
and not returned after the operation.
Instead, they were fed bread and milk until
28 days old. Water and rodent cake were
continuously available.
The thymus was removed by suction
under ether anaesthesia, having first split
the first 3 sternebrae and removed the
sternothyreoideus muscle. The skin wound
was closed with 2 clips and the animals
placed in an incubator at 370 C for approxi-
mately one hour.
The thymuses were collected into medium
199 (Wellcome Reagents Ltd., Beckenham)
at 40 C. They were either injected into the
rabbits within 4 hours or transferred to
Fischer's medium (+10% dimethyl sulpho-
xide) and stored whole in liquid nitrogen
(-1950 C).
Preparation ofantithymocyte serum
Rabbits were injected intravenously,
twice, each time with thymocytes from 5
thymuses (2 x 107 to 5 x 107 cells). The
2 injections were made 2 weeks apart and
the animals bled out 7 days after the second
injection. The thymocyte suspension was
prepared by mincing the thymuses with
scissors, agitating in medium 199 and filtering
through a 150 ,t-mesh sieve. Dye exclusion
test using 0.025% nigrosine indicated that
more than 80% of the thymocytes were
viable irrespective of whether they were
" fresh " or had been stored for some weeks
in liquid nitrogen. The rabbits were injected
intramuscularly with 2000 iu of heparin one
hour before each intravenous injection of
cells.
The bleeding and collection ofserum were
carriedoutunderaseptic conditionstoremove
the necessity of filtering the serum. Each
batch of serum was cultured for micro-
organisms before use. The rabbits were
starved for 12 hours before bleeding out.
They were anaesthetized with sodium pento-
barbitone and the blood collected from a
cannula inserted into the abdominal aorta.
The blood was allowed to stand for one hour
at room temperature, then centrifuged and
the serum removed. After decomplementing
in a water bath at 560 C for 30 min, the
serum was divided into aliquots of 10 ml and
stored at -20° C. At the start of each
experiment serum from 20 rabbits was
thawed, pooled and checked for sterility.
Normal rabbit serum was prepared and stored
in a similar way.
Collection and storage of tumour specimens
The specimens of tumour from patients
were either implanted immediately or stored
in liquid nitrogen until required. The speci-
mens for storage were sliced into pieces 1 mm
thick and frozen in Fischer's medium (no
added glutamine). 10% dimethylsulphoxide
(DMSO) was added before freezing. It was
considered important to wait 20 min at room
temperature before freezing, to allow the
DMSO to penetrate the specimen. However,
a longer interval might allow toxic effects of
DMSO to be exerted. Freezing was carried
out in a Union Carbide BF-6 biological freezer
which fits into the top ofa 4-litre " Thermos "
flask. One litre of liquid nitrogen was suffi-
cient for the freezing process (2 hours) and
for the specimens to be held overnight until
theycouldbetransferred totheliquid nitrogen
tissue store.
Specimens of tumour or thymus were
thawed by placing immediately in water at
38° C. The specimens were removed from
the freezing medium used for storage within
10 min ofthawing.
Implantation oftumour specimens
Pieces of tumour measuring 2 x 1 x 1
mm were implanted into the hamsters when
they were 28 days old. Hamsters were
chosen of the same sex as the donor patient.
The tumour implantation was made into the
left cheek pouch using a trochar and cannula
and under ether anaesthesia. The tumour
was placed in the connective tissue between
the stratified squamous lining of the cheek
pouch and the retractor muscle of the cheek
pouch. The subcutaneous implantation was
made into the left flank. All implants were
measured weekly.
Immunosuppressive treatment
The ATS, or NRS, treatment was started
7 days after thymectomy (7 days before
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tumour implant); 05 ml of serum was
injected subcutaneously into the right flank
3 times a week for 7 weeks.
Control of potentially pathogenic bacteria
In pilot studies the hamsters occasionally
developed a fatal enteritis within 72 hours of
anaesthesia and implantation of the tumour.
With the addition to the drinking water of
sulphadimidine at 0-3 mg/ml, the enteritis
could be prevented. The sulphadimidine
was renewed every 48 hours and given to the
animals from one week after thymectomy to
the completion ofthe experiment.
Histopathology
Anautopsywas carried out onallhamsters
found dead or in extremis and on those killed
at the completion ofthe experiment 120 days
after tumour implantation. The lungs were
examined for macroscopic evidence ofmetas-
tases. The following tissues were fixed in
Bouin's fluid for histopathological examina-
tion: the lungs, thymic area, heart, liver,
duodenum, pancreas, colon, suprarenal,
kidney, testes or ovary and remnant of
implanted tumour.
RESULTS
Tumours metastasizing to lung
Fourteen of the 20 tumours studied
metastasized to the lungs (Table I). Of
the 65 animals that were found to have
lung metastases, 23 died as a result of
their metastases. In the remaining 42
TABLE I.-Progress of Tumours Implanted Subcutaneously and Into the Cheek Pouch
Tumour
Ca breast
Ca breast
Ca breast
Ca colon
Ca colon
Melanoma
(malignant blue naevus)
Melanoma
(metastasis)
Melanoma
(metastasis)
Rhabdomyosarcoma
Teratoma of testis
Ca larynx
Ca larynx
Hypernephroma
Fibrosarcoma
No lung metastases
Ca breast
Ca ovary
Ca colon
Ca rectum
Liposarcoma
Ca cheek
Implantation
No.
Site animals
S.C.* 4
C.p.* 4
S.C. 4
c.p. 5
s.c. 6
c.p. 7
C.p. 4
s.c. 3
c.p. 8
c.p. 4
s.c. 5
c.p. 5
S.C. 3
c.p. 5
S.C. 3
c.p. 3
c.p. 5
S.C. 6
c.p. 7
S.C. 5
S.C. 6
c.p. 5
s.c.
c.p.
S.C.
c.p.
S.C.
s.c.
s.c.
c.p.
s.c.
c.p.
5
5
7
3
4
5
5
5
4
6
Local growtht
0 + ++
4
3 1
4
3 2
5 1
6 1
4
3
5 3
3 1
2 3
1 4
3
3 2
3
3
5
4 2
6 1
5
6
3 2
5
4
5
3
4
4
3
4
4
5
1
2
1
2
1
1
* s.c. =subcutaneous; c.p. =cheek pouch.
t 0 No increase in size of implanted tumour; + Temporary increase in size of implanted
tumour (never greater than x 5); + + Increase in size of implanted tumour necessitating
destruction ofanimal.
No. animals
with lung
metastases
3
3
3
4
4
4
3
3
5
4
3
4
1
0
2
3
3
3
6
1
1
2
Implantation
to first death
(weeks)
12
16
12
8
13
13
16
10
13
12
13
12
12
16
14
16
16
15
14
6
12
13
16
16
16
16
16
16
16
16
16
16
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rIG. I.-rypernephroma proliferating in the lung of a hamster. The tumour had been implanted subcutaneously 6 weeks previously. H. and E. x 100.
FIG. 2.-Carcinoma of the breast proliferating in the lung of a hamster. The tumour had been implanted subcutaneously 16 weeks previously. H. and E. x 100.
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TABLE II.-Tumour Growth in Thymectomized plus ATS Treated and Sham-
thymectomized plwu NRS Treated Groups
Tumour
Implantation
A
No.
Site animals
Thymectomy plus ATS
Hypernephroma . . s.c.*
Ca breast . . . s.c.
Sham-thymectomy plus NRS
Hypernephroma . . s.c.
Ca breast . . . s.c.
5
6
Local growtht
0 + ++
5
. 5 1
5 . 5
6 . 6
No. animals Implantation
with lung to first death
metastases (weeks)
4
4
0
* 0
6
13
16
16
* s.c.=subcutaneous.
t 0 No increase in size of implanted tumour; + Temporary increase in size of implanted
tumour (never greater than x 5); + + Increase in size of implanted tumour necessitating
destruction ofanimal.
Animals in both thymectomy plus ATS and sham-thymectomy plus NRS groups were
implanted with tissue from the same hypernephroma, or Ca breast.
animals, lung metastases were observed
macroscopically when the animals were
killed at the end of the experiment, or on
subsequent microscopic examination of
the lungs.
With the exception of a hyper-
nephroma, which grew rapidly at the site
of implantation necessitating the destruc-
tion of the animal, growth at the site of
the implant was never extensive. In 112
of the 156 animals implanted, the volume
of the subcutaneous tumour failed to
increase above that of the implanted
specimen at any time. In the remaining
animals there was a temporary increase
in tumour size but never greater than 5
times that of the original implant. This
increased volume was not maintained for
longer than the first 6 weeks after implan-
tation, except in the case of a melanoma
implant in which the tumour remained
5 times the size of the implant until the
animal was killed at the conclusion of the
experiment.
There was no significant difference in
the local growth or metastatic spread
between tumours implanted in the cheek
pouch and those implanted subcu-
taneously.
Histopathology
Although many metastases were histo-
logically indistinguishable from areas in
the patient's tumour, others were less
differentiated. The lungs were subject to
a special search for metastases with 3 or
4 sections cut for each lobe. The other
organs were examined with one section
perorgan. Metastases wereobserved only
in lung tissue and not in other tissues.
Control groups for the immunosuppressive
effect of thymectomy plus ATS, and sham-
thymectomy plus NRS
None of the animals implanted
subcutaneously with hypernephroma or
carcinoma of the breast, and having
sham-thymectomy plus NRS, showed
any sign of tumour growth or metastasis.
In contrast, of the 5 thymectomized
animals implanted subcutaneously with
hypernephroma and treated with ATS, all
developed extensive local tumour and one
had macroscopical lung metastases when
killed at 6 weeks (Fig. 1). Of the 6
thymectomized animals implanted subcu-
taneously with carcinoma of the breast
and treated with ATS there was little or
no local growth (Table II), but 4 showed
lung metastases by 16 weeks (Fig. 2).
DISCUSSION
The present experiments show clearly
that human tumours can become estab-
lished and proliferate in the hamster.
The results of the control experiments
with hypernephroma and carcinoma of
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the breast indicate that this is due to
thymectomy and ATS treatment. They
do not indicate the relationship and
relative importance of thymectomy and
ATS.
The failure of tumours to thrive either
subcutaneously, or in the cheek pouch,
and yet to become established and
proliferate in the lungs cannot so far be
explained. In the animals with lung
metastases it would be difficult to account
for the rejection of the subcutaneous or
cheek pouch tumour solely in terms of
cell-mediated immunity. The subcu-
taneous and cheek pouch implants may
be more vulnerable because they stimulate
a local vasodilation and are thereby more
accessible to antibodies than the slowly
developing lung metastases. The latter
may have a less permeable vasculature.
A suggestion along these lines has been
made by Beverley and Simpson (1970) to
account for the persistence of well estab-
lished tumour xenografts in mice after
the cessation of ALS treatment. On
the other hand, failure to grow at the
site of implantation may not be due to
immunological factors.
It was surprising to find that migrating
tumour cells became established in the
lungs and not in other organs. In experi-
ments at present under way a more
extensive search of tissues is planned.
There is no constant and direct
relationship between the titre of lympho-
cyte agglutinating and cytotoxic anti-
bodies of ALS and its immunosuppressive
activity for allografts (Jeejeebhoy, 1967;
Gozzo, Wood and Monaco, 1971). There
seems no reason to think that these tests
will be any more relevant for assessing the
ability of ATS to enhance thymectomy in
xenografts. Darrow (1971) has reported
wide variations in cytotoxic antibody
titre between individual rabbits, which
could be markedly reduced by pooling
serum from 5 rabbits. In the present
work serum was pooled from groups of
20 rabbits.
The hamster cheek pouch has
frequently been reported as a site offering
to xenografts a degree of protection from
immunological attack (Toolan, 1955).
The fact that such protection was not
observed in the present experiments may
have been associated with the " severitv
of the immunosuppression obtained with
thymectomy plus ATS.
It is likely that the lung metastases
arose from single " clonogenic " cells
migrating from the site of implantation.
It is known that human tumour cell
populations vary greatly in their median
intermitotic time and cell loss fraction
(Steel, 1972). If the "clones" had a
short median intermitotic time and a
small cell loss fraction, they might be
expected to be macroscopically visible
within 4 to 6 weeks of commencing
proliferation in the lungs. With leng-
thening median intermitotic times and
greater cell loss fractions, the macroscopic
appearance of metastases may be delayed
for weeks or months.
The ATS was stopped 6 weeks after
implantation of the tumour and 10 weeks
before the animals were killed at the
termination of the experiment. This
withdrawal ofATS did not lead invariably
to the rejection of lung metastases,
possibly because the animals had been
thymectomized (Jeejeebhoy, 1965).
The growth and metastasis of human
tumour material in an experimental
animal can provide a useful tool in the
study of the metastatic process. It may
also be of use in the evaluation of a
patient's likely response to treatment,
although it will be some time before the
areas of similarity between the growth of
tumour in the patient and that in the
hamster can be mapped out.
I wish to thank Miss R. Ellis for the
histological preparations. This investi-
gation was supported by grants to the
Chester Beatty Research Institute (Insti-
tute of Cancer Research, Royal Cancer
Hospital) from the Medical Research
Council and the Cancer Research
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